Compare Stocks → Your $200 account credit is about to expire (From MarketBeat) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:INNASDAQ:VIRNYSEAMERICAN:ZOM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINInMed PharmaceuticalsC$4.19C$3.35▼C$13.86C$33.73MN/A29,552 shs17,035 shsVIRVir Biotechnology$10.10+1.3%$10.18$7.72▼$27.48$1.36B0.421.11 million shs995,068 shsZOMZomedica$0.14$0.00$0.12▼$0.25$140.92M0.985.55 million shs5.69 million shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINInMed Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VIRVir Biotechnology+1.30%-0.69%-15.13%-1.85%-55.31%ZOMZomedica0.00%0.00%+2.53%-14.55%-35.12%Crypto Market Preps For Trillions Worth of Inflows! (Ad)Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online EventMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINInMed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology1.9657 of 5 stars3.31.00.00.01.13.31.3ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINInMed PharmaceuticalsN/AN/AN/AN/AVIRVir Biotechnology2.57Moderate Buy$34.38240.35% UpsideZOMZomedicaN/AN/AN/AN/ACurrent Analyst RatingsLatest ZOM, VIR, and IN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.002/23/2024VIRVir BiotechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$9.00 ➝ $10.002/14/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $110.001/29/2024VIRVir BiotechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$23.00 ➝ $9.001/23/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$95.00 ➝ $85.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINInMed PharmaceuticalsC$574.68K0.00N/A10.40C$0.76 per share0.00VIRVir Biotechnology$86.18M15.83N/AN/A$11.82 per share0.85ZOMZomedica$18.93M7.44N/AN/A$0.27 per share0.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINInMed PharmaceuticalsN/A-C$1.51N/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology-$615.06M-$4.59N/AN/AN/A-713.69%-34.92%-27.73%5/2/2024 (Estimated)ZOMZomedica-$17.01M-$0.03N/AN/AN/A-62.21%-5.68%-5.38%5/9/2024 (Estimated)Latest ZOM, VIR, and IN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/22/2024Q4 2023VIRVir Biotechnology-$1.14-$0.86+$0.28-$0.86$11.18 million$16.80 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINInMed PharmaceuticalsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINInMed Pharmaceuticals8.482.131.45VIRVir BiotechnologyN/A9.059.05ZOMZomedicaN/A17.1216.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINInMed PharmaceuticalsN/AVIRVir Biotechnology65.32%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipINInMed PharmaceuticalsN/AVIRVir Biotechnology18.10%ZOMZomedica4.18%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableINInMed Pharmaceuticals128.05 millionN/ANot OptionableVIRVir Biotechnology587135.03 million110.59 millionOptionableZOMZomedica85979.95 million938.99 millionNot OptionableZOM, VIR, and IN HeadlinesSourceHeadlineZomedica (NYSEAMERICAN:ZOM) Trading 4.7% Higher americanbankingnews.com - March 27 at 1:00 AMZomedica to Report Fourth Quarter and Full Year 20…pharmiweb.com - March 20 at 9:17 AMZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETaccesswire.com - March 20 at 6:30 AMZomedica Pharmaceuticals Corp (ZOM)investing.com - March 15 at 7:52 AMZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platformaccesswire.com - March 14 at 6:30 AMZomedica Provides NYSE American Listing Updateaccesswire.com - March 13 at 4:45 PMSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conferencefinanznachrichten.de - March 12 at 11:26 AMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesfinanznachrichten.de - March 12 at 8:22 AMZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesaccesswire.com - March 12 at 6:30 AMZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogsaccesswire.com - March 7 at 6:30 AMZomedica to Present at the Sidoti Small Cap Conference March 14, 2024accesswire.com - March 5 at 6:30 AMZomedica Pharmaceuticals Corp. (ZOM)uk.finance.yahoo.com - March 1 at 2:46 PMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinanznachrichten.de - February 8 at 9:14 AMZomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferencesfinance.yahoo.com - February 8 at 9:14 AMZomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidationfinanznachrichten.de - February 6 at 5:00 PMLeading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)finance.yahoo.com - February 6 at 5:00 PMZomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ETfinance.yahoo.com - February 6 at 7:00 AMZomedica Corp. (ZOM) Interactive Stock Chart - Yahoo Financefinance.yahoo.com - February 4 at 8:05 AMInsider Buying: POWERS JOHNNY D, Zomedica Corp [ZOM] Director invested 100,000 sharesknoxdaily.com - February 2 at 4:11 PMWorld dermatology congress, Nextmune acquires Vetbiotek, and moredvm360.com - January 31 at 5:54 PMGrip Molecular Aims for 2027 Launch of Home-Use Graphene Biosensor Assays360dx.com - January 31 at 5:54 PMOpen Letter to Zomedica Shareholders from your Chief Executive Officerfinance.yahoo.com - January 31 at 6:59 AMZomedica Corp Ordinary Sharesmorningstar.com - January 30 at 3:51 PMZomedica Corp.: Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidationfinanznachrichten.de - January 17 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines4 Stocks to Buy Before the Fed Cuts Interest RatesMarch 19, 2024 7:49 AMView 4 Stocks to Buy Before the Fed Cuts Interest RatesKohl’s Corporation: This Offprice Retailer Is Ready To RallyMarch 1, 2024 10:55 AMView Kohl’s Corporation: This Offprice Retailer Is Ready To RallyGrowing Twice as Fast as Tesla, XPeng is a BuyMarch 19, 2024 12:03 PMView Growing Twice as Fast as Tesla, XPeng is a BuyThis Freight Stock Just Got an Upgrade and Institutional BuyersMarch 13, 2024 9:51 AMView This Freight Stock Just Got an Upgrade and Institutional BuyersIntuitive Machines: Charting a Course Among the StarsMarch 21, 2024 11:30 AMView Intuitive Machines: Charting a Course Among the StarsAll Headlines Company DescriptionsInMed PharmaceuticalsTSE:INInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Vir BiotechnologyNASDAQ:VIRVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.ZomedicaNYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.